文献速递肿瘤 PET/CT核素与放射性配体治疗

切伦科夫发光成像是一种有效的临床前工具用于评估结直肠癌PD-L1表达水平

Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo.
PubMed 文献 · EJNMMI Res · 2020-06-15

本研究开发了131I标记的抗PD-L1单克隆抗体示踪剂131I-PD-L1-Mab,在结直肠癌荷瘤小鼠模型中通过生物分布和切伦科夫发光成像评估肿瘤PD-L1表达。结果显示该示踪剂对PD-L1具有高亲和力,平衡解离常数为1.069×10-9 M,在四种不同PD-L1表达的荷瘤模型中,RKO肿瘤摄取最高,48小时最大摄取为1.613±0.738% IA/g。结论认为131I-PD-L1-Mab无创切伦科夫发光成像在评估肿瘤PD-L1表达状态和筛选抗PD-L1靶向治疗患者方面具有很大潜力。

要点

  • 131I-PD-L1-Mab对PD-L1的平衡解离常数为1.069×10-9 M,具有高亲和力。
  • 在四种不同PD-L1表达的荷瘤模型中,RKO肿瘤摄取最高,48小时最大摄取为1.613±0.738% IA/g。
  • 131I-PD-L1-Mab无创切伦科夫发光成像有潜力评估肿瘤PD-L1表达并筛选抗PD-L1治疗患者。

核心结论

  • 131I-PD-L1-Mab无创切伦科夫发光成像在评估肿瘤PD-L1表达状态和筛选抗PD-L1靶向治疗患者方面具有很大潜力。

研究设计与样本

  • 临床前研究,开发了131I标记的抗PD-L1单克隆抗体示踪剂131I-PD-L1-Mab,在结直肠癌荷瘤小鼠模型中进行体外结合实验、生物分布和切伦科夫发光成像。

主要发现

  • 131I-PD-L1-Mab对PD-L1具有高亲和力,平衡解离常数为1.069×10-9 M。
  • 竞争抑制实验进一步证实了131I-PD-L1-Mab的特异性结合能力。
  • 在四种不同PD-L1表达的荷瘤模型中,生物分布和切伦科夫发光成像显示RKO肿瘤对131I-PD-L1-Mab的摄取最高,48小时最大摄取为1.613±0.738% IA/g。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in the tumors. A 131I-labeled anti-PD-L1 monoclonal antibody tracer, 131I-PD-L1-Mab, was developed to study the target ability of noninvasive Cerenkov luminescence imaging in colorectal cancer xenograft mice. METHOD: Anti-PD-L1 monoclonal antibody labeled with 131I (131I-PD-L1-Mab), and in vitro binding assays were used to evaluate the affinity of 131I-PD-L1-Mab to PD-L1 and their binding level to different colorectal cancer cells, and compared with flow cytometry, Western blot analysis, and immunofluorescence staining. The clinical application value of 131I-PD-L1-Mab was evaluated through biodistribution and Cerenkov luminescence imaging, and different tumor-bearing models expressing PD-L1 were evaluated. RESULTS: 131I-PD-L1-Mab showed high affinity to PD-L1, and the equilibrium dissociation constant was 1.069 × 10-9 M. The competitive inhibition assay further confirmed the specific binding ability of 131I-PD-L1-Mab. In four different tumor-bearing models with different PD-L1 expression, the biodistribution and Cerenkov luminescence imaging showed that the RKO tumors demonstrated the highest uptake of the tracer 131I-PD-L1-Mab, with a maximum uptake of 1.613 ± 0.738% IA/g at 48 h. CONCLUSIONS: There is a great potential for 131I-PD-L1-Mab noninvasive Cerenkov luminescence imaging to assess the status of tumor PD-L1 expression and select patients for anti-PD-L1 targeted therapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhao S, Pan W, Jiang H, et al. Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo. EJNMMI Res. 2020. PMID: 32542442. doi:10.1186/s13550-020-00654-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。